AI Adoption Accelerates in Spain’s Self-Care Sector

Half of the self-care companies surveyed have an AI implementation plan, and 59.1% of them claim to have a specific department to address all issues related to artificial intelligence.

That is according to the 1st Artificial Intelligence Index in the Self-Care sector, prepared by the Association for Self-Care in Health (Anefp), whose objective is to measure the degree of implementation in companies in Spain.

Regarding the main objectives that companies seek in their ArtificiaI Intelligence implementation strategies, the following stand out:

Optimizing processes and being more efficient (90%), providing added value and improving analytics and data management (45.5%); improving product and service personalization, the customer experience, and reducing costs (27.3%); and having a competitive advantage and fostering innovation in the development of new products (22.7%).

As for the obstacles identified in achieving these objectives, companies mention a lack of training in teams, a lack of digital culture, and insufficient human and financial resources, in addition to legal and data protection limitations.

For Jaume Pey, CEO of Anefp, “this first Index in the self-care sector allows us to have a current snapshot of how companies in the self-care sector are facing the challenge of Artificial Intelligence, what obstacles they are encountering, as well as the challenges and opportunities that artificial intelligence offers us to provide a better service to citizens in the self-care of their health.”

Regarding the level of digital maturity in this new sector, 40.9% of the companies surveyed indicate that it is high, although a majority, 59.1%, consider it currently low. “We have a way to go, as evidenced by data such as the fact that 63.6% state that the implementation will be a strategic pillar in the future, a future that is already the present for 22.7%,” noted Jaume Pey.

This first Index in the Self-Care sector, promoted by the AI ​​Working Group of anefp, also shows that 45.5% are fostering a culture in their company, and up to 36.4% are already evaluating it. Regarding the implementation of training initiatives, 54.4% are already carrying them out, mainly through training in language models, tutorials, Artificial Intelligence working groups, forums, webinars, and specific training for each area.

Tools such as ChatGPT, Copilot, Azure, Perplexity, Writer, and other specific scientific information tools are already used by 73% of self-care companies, with a positive assessment from 61% and 39% stating they need more time to evaluate them

Regarding the future, companies point to ensuring data privacy, intellectual property, and literacy, among other challenges posed by the new tools. They emphasize that Artificial Intelligence will bring more value in the future to areas related to process optimization and efficiency, marketing, CRM and customer experience, and clinical trials, sustainability, and science.

As for investment in the sector, 66.7% of companies state that they will invest more than they do now in the short and medium term, while 23.8% underline that they will maintain their current investment level.

__

(Featured image by Alexander Sinn via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in diariofarma. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.